Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

MLA

Stone, Richard M., et al. “Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.” The New England Journal of Medicine, vol. 377, no. 5, Aug. 2017, pp. 454–64. EBSCOhost, https://doi.org/10.1056/NEJMoa1614359.

APA

Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., Lo-Coco, F., Klisovic, R. B., Wei, A., Sierra, J., Sanz, M. A., Brandwein, J. M., de Witte, T., Niederwieser, D., Appelbaum, F. R., … Döhner, H. (2017). Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. The New England Journal of Medicine, 377(5), 454–464. https://doi.org/10.1056/NEJMoa1614359

Chicago

Stone, Richard M, Sumithra J Mandrekar, Ben L Sanford, Kristina Laumann, Susan Geyer, Clara D Bloomfield, Christian Thiede, et al. 2017. “Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.” The New England Journal of Medicine 377 (5): 454–64. doi:10.1056/NEJMoa1614359.